Advantages of n-CoDeR® library

  • Wider variety of antibodies than found in nature
  • Fully human antibodies with low inherent immunogenicity
  • High level of target specificity
  • High level of target affinity
  • High levels of functionality, stability and expression
  • Choice of formats to suit application (scFV and Fab available)

 

 nCoDeR

Reduced development times

  • Rapid automated screening with Robo-CoDeRTM
  • Cassette vector system for different antibody formats
  • Parallel transient expression systems for rapid scale-up
  • Streamlined process development

n-CoDeR®

The n-CoDeR® antibody library contains 20 billion (2 x1010) human antibody genes. All the antibodies have the same framework structure, which has low immunogenicity. However, each antibody has a unique combination of Complementarity Determining Regions (CDRs), which defines its antigen binding specificity. These CDRs were originally isolated from the antibodies of a large number of healthy volunteers. Using the n-CoDeR® technology the fully human CDRs are recombined into new antibody molecules. The unique recombination process allows the library to contain a wider variety of antibodies than could have been created naturally by the human immune system. This means that there is a higher likelihood of finding antibodies with high affinity and high specificity against a particular target.

Two library formats exist, one containing the smaller scFv antibody fragment and the other containing the Fab antibody fragment. Antibodies from the library are selected using an established technology called phage display. Selected targets are used as bait to fish out those antibodies that bind to the target. As n-CoDeR® is an in vitro system, the bait can take any format including cells, proteins or peptides. The relevant antibody genes can then be produced within the bacteria, E. coli.

We have developed an integrated robotics platform for the rapid selection, screening and identification of human antibodies from our n-CoDeR® library. The Robo-CoDeRTM platform has the capacity to screen more than twenty thousand antibody clones each day. Antibodies isolated from n-CoDeR® have shown affinities in the sub-nanomolar range against haptens, peptides, carbohydrates and proteins.

The n-CoDeR® library is protected by patents and patent applications in all markets of commercial interest.

BioInvent International • SE-223 70 Lund, Sweden • Visiting: Sölvegatan 41, Lund, Sweden • Tel: +46 (0)46-286 85 50 • E-mail: info@bioinvent.com